{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"Percent of participants alive at follow-up time. Overall survival time is evaluated from the date of treatment to date of death, and to date of last follow-up for those still alive.","groups":[{"description":"docetaxel: Beginning on week 3, patients receive docetaxel IV over 1 hour once a week","id":"OG000","title":"Oral Erlotinib Hydrochloride"}],"paramType":"NUMBER","populationDescription":"Participants enrolled in study","reportingStatus":"POSTED","timeFrame":"3 years","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"Percent"}